Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(319)
•••
Post by Claridgeon Jun 18, 2019 7:50pm
110 Views
Post# 29838063

The GBM cocktail ...

The GBM cocktail ...The GBM cocktail:

GBM cocktail =  Immune Response from PDT + PDT/PDC with Rutherrin + Anti-Cancer Vaccine + Destruction of cancer stem cells (CSC) by PDT + cannabioid ("1 + 1 = 3")
 
and its associated press releases:

- November 30, 2018 - Theralase’s Rutherrin® Photo Dynamic Therapy Induces Immune Response to Destroy Human Brain Cancer Cells
- June 11, 2018 - Theralase Demonstrates Significant Advantage in Treatment of Brain Tumours 
- March 27, 2018 - Theralase Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer
- March 15, 2018 - Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
- January 17, 2018 - Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer
- November 20, 2017 - Theralase Discovers New Anti-Cancer Vaccine
- September 25, 2017 - Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays
- October 28, 2016 - Theralase Increases GBM Brain Cancer Survival by 925%
- October 13, 2016 - Theralase Demonstrates Significant Increase in Survival for Brain Cancer



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities